Veeva Systems (VEEV) Investor Day 2024 summary

Vision and strategy

• Announced a new 2030 revenue goal of $6 billion, aiming to double revenue from 2025 to 2030, primarily through organic growth in life sciences and existing products.

• Entering major new markets with a focus on horizontal enterprise applications, building a next-generation application platform with a small, autonomous team.

• Emphasizes a durable, values-driven operating model, prioritizing product excellence, customer success, and employee success as a public benefit corporation.

• Pursues a platform-first approach and long-term planning, supporting adaptability, innovation, and execution.

• Aims to build the industry cloud for life sciences, focusing on software, data, and business consulting.

Market opportunity and product strategy

• Life sciences industry TAM exceeds $20 billion, with current penetration at 14% and a 6%+ CAGR.

• Product suite spans regulatory, quality, clinical, and commercial, with over 50% of future growth expected from existing products.

• Ongoing innovation includes new products in clinical and commercial clouds, with future launches planned.

• AI strategy centers on application-specific bots, integration of large language models, direct data APIs, and a partner program to accelerate data-driven processes.

• Average products per customer continue to rise in both R&D and commercial segments.

Financial performance and guidance

• Q3'25 revenue guidance: $682–685M total, ~$571M subscription, $111–114M services, $273–275M non-GAAP operating income.

• FY25E revenue expected at $2.71B, with a non-GAAP operating margin of 41%.

• Subscription revenue, currently 83% of total, expected to rise to 87% by 2030, with services growing at a slower pace.

• Maintains a non-GAAP operating margin floor of 35%, with disciplined investment in new markets and a focus on profitable growth.

• Consistent profitability, with non-GAAP operating margins historically in the 35–41% range.